ABSTRACT
Death of dopaminergic neurons, in substantia nigra pars compacta, results in exsanguinations of neurotransmitter dopamine in corpus striatum and motor symptoms of Parkinson disease. However, deterioration of non-dopaminergic neurons, such as serotonergic and noradrenergic neurons, became one of fixed truths of Parkinson disease. It was suggested that these neurons deterioration has a role in motor symptoms, in addition to non-motor symptoms, such as depression, imperceptions and sleep disorders. So, the aim of research was testing Buspirone effect, a partial agonist of 5-HT[1A] auto serotonergic receptors, for improvement of Parkinsons' symptoms in Wister adult albino male rats with Parkinson disease caused by Reserpine [3 mg/kg]. And study of Buspirone effect on L-DOPA therapeutic activity and its important for dyskinesia treatment resulted from long term therapy with L-DOPA. The current study illustrated that low dosages of Buspirone [0.25, 1, 3 and 6 mg/Kg] improved the affected rats' movement, whereas high dosage [10 mg/kg] didn't improve the movement, by comparing these groups with control group which has injected with injected water. Also, this study revealed that Buspirone lows the therapeutic activity of L-DOPA, by comparing the motor behavior of affected groups, which treated with Buspirone [3, 6 and 10 mg/kg]+L-DOPA [100 mg/kg], with that treated only with 100 mg/kg of L-DOPA. As conclusion, our study appears Buspirone efficiency to improve the symptoms of Parkinson disease in animal samples, as it gives an area for clinical experiments for testing the effect of Buspirone [currently used for anxiety treatment] on Parkinson disease's symptoms, in patients suffering from side effects of L-DOPA